

# ADDIS MCDA tutorial

## Contents

<a href="#">Tutorial 1: manual data entry</a>	<b>1</b>
<a href="#">Appendix to Tutorial 1</a>	<b>9</b>
<a href="#">Tutorial 2: effects table building</a>	<b>11</b>
<a href="#">Tutorial 3: multi-criteria decision analysis</a>	<b>17</b>
<a href="#">Tutorial 4: sensitivity analysis</a>	<b>26</b>

## Tutorial 1: manual data entry

This tutorial guides you through the process of manually entering data, so that you can create your own effects tables.

### Subjects covered

- Manual data entry interface
- Defining criteria and alternatives
- Specifying references
- Filling in the data entry table


## Example effects table

The data that you are going to enter in this tutorial is taken from the effects table for lixisenatide as included in the [EMA Guidance document for critical assessment reports](#) (see page 72). For didactic purposes, we are going to work with a simplified version of that table which includes HbA1c as a favourable effect and nausea as an unfavourable effect (Figure 1).

Effect	Description	U	LIX	PBO	Uncertainties / Strength of evidence	Reference
Favourable Effects						
HbA1c	Mean change in HbA1c from baseline	%	-0.83 (-0.91, -0.75)	-0.39 (-0.51, -0.28)	Unc: The effect of lixisenatide was more pronounced in Asian patients compared to Caucasian patients. The lower effect in Caucasians is partly explained by a large placebo effect especially in some geographical regions.	Pooled data from EFC6014 and EFC10743
			-0.82 (-0.91, -0.73)	-0.10 (-0.24, 0.04)		EFC6015
Unfavourable Effects						
Nausea	Incidence of nausea	%	26.9	7.3		pooled data from all phase 2/3 controlled studies


Figure 1: Simplified effects table for lixisenatide, a treatment for type 2 diabetes mellitus


## Sign in to MCDA.drugis.org


 Open your browser and navigate to <https://mcda.drugis.org>. Use your Google account to sign in. You will be redirected to your personal homepage,

containing your previously created workspaces, both finished and unfinished (if any).


## Create a new workspace


 Press the ‘Add workspace’ button, select the option ‘Create new workspace’, and press the ‘Add’ button. This leads to the first step of the manual entry process.


 A workspace contains the clinical efficacy and safety data that you have entered for a particular benefit-risk assessment. Within a workspace you can build effects tables and perform quantitative benefit-risk analyses. Existing workspaces are opened by clicking on their name, or navigating to their URL directly via a link or bookmark. Workspaces can only be accessed by their owner.

 We here cover the manual workspace creation process; besides this you can also create workspaces based on example data uploaded by the ADDIS team, and upload JSON files exported by you or another user.


## Enter general information


 Enter a descriptive title in the ‘Workspace title’ field at the top of the page. For example, “lixisenatide data entry tutorial”.


 Enter the indication and other relevant context for your assessment in the ‘Therapeutic context’ field. For example, “Assessment of lixisenatide for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in patients not adequately controlled on oral antidiabetics.”


 Any changes you make are automatically saved. You can select this in-progress workspace from your personal homepage later, and continue where you left off. You can navigate back to your home page by pressing the [mcda.drugis.org](http://mcda.drugis.org) link on the menu bar at the top-left of the screen.

## Criteria and favourability


 Criteria are the clinical efficacy and safety outcomes in terms of which the treatments under consideration are evaluated. A criterion has a name (a short identifier, such as “HbA1c” or “Nausea”), and a description. The description specifies how the effect of a treatment on the selected outcome variable is measured statistically. For example, for “HbA1c” this could be “mean change of HbA1c from baseline” or “proportion of patients with a normal HbA1c value at week 24”.

 For regulatory purposes, criteria can additionally be classified as favourable or unfavourable, with favourable criteria being ones where the new treatment under consideration outperforms the status quo.


 The effects table for lixisenatide divides the criteria into favourable and unfavourable effects. To enable this classification, ensure that the ‘Use favourability’ box below the ‘Criteria’ heading is checked.

 A fresh workspace is pre-initialised to include two criteria and two alternatives by default, with generic names. You can add further alternatives, criteria and references using the ‘+’ buttons, and delete them with the garbage bin icons.

## Add the HbA1c criterion

 Change ‘criterion 1’ to ‘HbA1c’ by clicking its title and changing the value in the text box. Similarly, change the description to be ‘Mean change of HbaA1c from baseline’.

## Add two references for HbA1c

 For each criterion, there can be one or more references from which summary statistics or treatment effect estimates are taken. A reference can be a single pivotal study but could also be a pooled analysis, such as a combined safety pool or a (network-) meta-analysis. Its origins are specified via its name (the ‘Reference’ field) and optionally its URL.

☞ For the HbA1c criterion, edit the existing reference, by clicking on the last cell in the row, and fill in the dialog to be “Pooled data from EFC6014 and EFC10743”, leaving the ‘Reference URL’ field empty. After closing the dialog, the reference should now display your changes. Click the ‘Add reference’ button (the ‘+’ symbol) just below this row. A second reference row will appear. Edit this one so the reference is “EFC6015”, again leaving the ‘Reference URL’ field empty.

## Add nausea as an unfavourable effect

☞ Edit ‘criterion 2’ to be called ‘Nausea’ and set its description to ‘Incidence of nausea’. Then, change it from a favourable to an unfavourable effect by clicking the icon on the left of the row, with the thumb pointing down.

☞ Change the reference to “Pooled data from all phase 2/3 controlled studies”. There are no further references for this criterion.

## Add lixisenatide and placebo as alternatives

☞ Rename ‘alternative 1’ by clicking on it and entering ‘lixisenatide’ in the text box. Rename ‘alternative 1’ to ‘placebo’.

## Set the units of measurement

☞ We can set the unit of measurement for each reference. To do so, click on the ‘Unit of measurement’ cell.

☞ For ‘HbA1c/Pooled data’, leave the type on ‘Custom’ and add the Label ‘Percentage point’. Do the same for ‘HbA1c/EFC6015’.

☞ For the Nausea reference, select ‘Proportion (percentage)’ as the unit of measurement.

## Proceed to data entry

### Effect and Distribution modes

💡 Data entry is split into two modes – Effect and Distribution – and you can switch freely between them using the dropdown above the effects table. In this tutorial, we will be mainly using the Effect mode.

🎓 Data about effects can be entered either as effects or distributions. An overview of the various data entry possibilities is provided in the [Appendix to Tutorial 1](#).

### Add Strength of evidence/Uncertainties

🎓 The ‘Uncertainties’ and ‘Strength of evidence’ fields describe any strengths and weaknesses of the study design, quality of the data collection and analysis, generalizability of the study findings, etc.

📖 We will add the following Uncertainty to the ‘HbA1c/Pooled data’ reference: “The effect of lixisenatide was more pronounced in Asian patients compared to Caucasian patients. The lower effect in Caucasians is partly explained by a large placebo effect especially in some geographical regions.” To do so, click the ‘Unc’ text and fill in the text box.

### Enter data

📖 Click on the ‘No value entered’ text in the cell for HbA1c’s ‘pooled data from EFC6014 and EFC10743’ row and lixisenatide column. Fill out the dialog as shown in Figure 2, and click anywhere on the page outside of the dialog to close it.

📖 Proceed to fill out the remaining three cells for HbA1c with the point estimates and 95% confidence intervals from Figure 1.

📖 Similarly, fill out the cells for Nausea with the values from Figure 1, selecting ‘Value’ as the input parameter. Your final data entry table should look like Figure 3.

💡 If required, cells can be left empty by choosing the ‘Empty cell’ as the input parameter.

Input parameters

Value, 95% C.I. ▼

Value

-0.83

Lower bound ( ☐ Not estimable)

-0.91

Upper bound ( ☐ Not estimable)

-0.75

Figure 2: Data entry dialog for HbA1c.

Use favourability ☒ ?


Table input mode 

Effect

Criterion?	Description		Unit?	Lixisenatide	Placebo	+	Strength of evidence? and Uncertainties?	Reference?
Favourable criteria								
<div><div></div><div></div></div>	HbA1c	Mean change in HbA1c from baseline	<div><div></div><div></div></div>	Percentage point [-Infinity, Infinity]	-0.83 (-0.91, -0.75)	-0.19 (-0.43, -0.05)	<div>SoE: click to edit</div> <div>Unc: The effect of lixisenatide was more pronounced in Asian patients compared to Caucasian patients. The lower effect in Caucasians is partly explained by a large placebo effect especially in some geographical regions.</div>	Pooled data from EFC6014 and EFC10743
			<div><div></div><div></div></div>	Percentage point [-Infinity, Infinity]	-0.82 (-0.91, -0.73)	-0.1 (-0.24, -0.04)	<div>SoE: click to edit</div> <div>Unc: click to edit</div>	EFC6015
			<div><div></div><div></div></div>					
<div><div></div><div></div></div>								
Unfavourable criteria								
<div><div></div><div></div></div>	Nausea	Incidence of nausea	<div><div></div><div></div></div>	% [0, 100]	26.9	7.3	<div>SoE: click to edit</div> <div>Unc: click to edit</div>	Pooled data from EFC6014 and EFC10743
			<div><div></div><div></div></div>	<div><div></div><div></div></div>				
<div><div></div><div></div></div>								


Figure 3: Final data entry table for lixisenatide.


## Generate distributions

 If a user wishes to work with distributions and perform SMAA analyses but the data is provided as effects only, it is possible to automatically generate the distributions. To do so, click the ‘Generate distributions’ button. Doing this will take you to the Distributions view, where the automatically generated distributions are shown. Please see the [Appendix to Tutorial 1](#) to see which effect input types are converted into which distribution types.


## Finalize entry


You have now finished preparing your effects table for analysis.

 Click ‘Done’ and you will go to the overview page of your newly-created workspace where you will find the entered effects table.

 After finishing the manual entry process, cosmetic properties such as names and descriptions can still be edited, and the criteria can be re-ordered using the arrow buttons. However, to prevent breaking the analyses that are based on them, measurements cannot be modified. Changing measurements can be done by creating a copy of the workspace on your homepage. This begins a new manual entry process as detailed above, but all criteria, alternatives and measurements are already filled out based on the old workspace, and can be changed at will.

## Export and share with others

 On your newly-created workspace, click ‘Download workspace’ in the top-left to save a .json file which contains all the data you just entered. When creating a new workspace, you can upload this file (using the ‘local file’ option) and the new workspace will contain a copy of your data.

 Sending this file via e.g. email to someone else is the recommended way to share workspace data with other users. In the [Enterprise version](#) of our software, you can also grant access to others directly within the application.



## Appendix to Tutorial 1: reference characteristics and data entry options

A treatment effect is a statistical parameter that describes how a given treatment affects the distribution of a criterion in the target population (i.e., all patients for which the evaluated treatment is indicated). The representation of that parameter's uncertainty in the effects table depends on the specified characteristics of the row's reference. Indicating that the input type is 'Distribution' corresponds to a Bayesian perspective, where the uncertainty is quantified by means of probability distributions. The option 'Effect' corresponds to a frequentist perspective where parameters are treated as fixed but unknown constants for which point and interval estimates (e.g., 95% confidence intervals) are provided.

### Types of distributions (Bayesian)

Distributions can be specified directly by choosing a type of distribution and entering its parameters, or derived indirectly from summary statistics from a clinical study (option 'Generate distributions'). When this latter option is selected, a Bayesian posterior distribution (i.e., a beta distribution for the event probability of a dichotomous outcome variable and a normal distribution for the mean of a continuous outcome variable) is estimated from the summary statistics supplied by the user and a reference prior set by the system.

The following types of distribution are supported:

- Beta
- Normal
- Gamma
- Value (i.e., degenerate distribution that always results in the same value)
- Range

Distributions of the type 'Value' and 'Range' can be input either as percentages, decimals, or neither, see Section .

## Types of effects (Frequentist)

The following data entry options are currently available for effects:

- Value
- Value, 95% confidence interval
- Range

These effects can be input either as percentages, decimals, or neither, see Section .

## Unit of measurement

The following units of measurement are supported:

- Custom: you can input a custom label and any lower and upper bounds.
- Proportion (decimal): label will be set to 'Proportion', and lower and upper bounds to 0 and 1, respectively.
- Proportion (percentage): label will be set to '%', and lower and upper bounds to 0 and 100, respectively.

You can switch between 'Percentages' and 'Decimals' views by changing the workspace settings (accessed by clicking the 'settings' button at the top right of the screen for any finished workspace). This will automatically scale the values were possible, i.e. datasources with either 'Proportion (decimal)' or 'Proportion (percentage)' unit of measurement.

The user can enter '%' as a label for a custom unit of measurement for a reference. However, switching between 'Percentages' and 'Decimals' views will not scale the values in this case.

## Tutorial 2: effects table building

This tutorial guides you through the process of making analysable effects tables out of larger datasets.


### Subjects covered

- Problem definition interface
- Creating effects tables of subsets of your measurements data
- Switching between effects tables


### Example effects table

The data that you are going to enter in this tutorial is taken from the effects table for lixisenatide as included in the [EMA Guidance document for critical assessment reports](#) (see page 72). We use a similar table to the previous tutorial, with one more criterion and alternative.


### Sign in to MCDA.drugis.org

 Open your browser and navigate to <https://mcda.drugis.org>. Use your Google account to sign in. You will be redirected to your personal homepage, containing your previously created workspaces, both finished and unfinished (if any).

### Create a new workspace

 Press the ‘Create workspace’ button, click ‘Select tutorial workspace’, load the ‘Lixisenatide simplified’ example, and press the ‘Add’ button. This takes you to the overview screen. Take a moment to look at the criteria, alternatives, and data sources.

### Create an analysable effects table

 Click on the ‘Problem definition’ tab. Note that the currently-selected problem (in the dropdown at the top of the screen) is the ‘Default’ problem. This problem is always automatically generated by the system and includes

all criteria, alternatives, and data sources shown on the ‘Overview’ tab.

🎓 A ‘problem’ is our term for an analysable selection of criteria, alternatives, and data sources from those available in the workspace. This selection can include everything in the workspace, but several restrictions apply:

- Only one data source can be selected per criterion
- No missing measurements (empty cells) are allowed for any combination of the selected criteria/alternatives

An exception is the ‘Default’ problem, which may contain multiple data sources as well as empty cells. Should this be the case, the ‘Default’ problem is considered to be not analysable, resulting in an inactive ‘Preferences’ tab. Hovering your mouse over the ‘Preferences’ tab will then show a tooltip explaining why this tab is inactive.

🖱️ Click the ‘+’ icon next to the ‘Problem’ dropdown (Figure 4). This opens the problem creation dialog.




Figure 4: Problem creation button

🖱️ Take a look at the warnings in red near the bottom of the dialog. These explain why the current selection of criteria, alternatives, and data sources is not analysable. To make the effects table analysable, first, deselect the Exenatide criterion and then deselect the data source rows for EFC6019. This should cause the warning about missing values to disappear. Next, deselect the data source rows for EFC6015, so that we end up with a lixisenatide/placebo comparison based on pooled data EFC6014 and EFC10743 for HbA1c and Hypoglycaemia. Now the warning about multiple data sources should have disappeared (Figure 5). The controls for setting the scale ranges

(the breadth of possible values to assess on the ‘Preferences’ tab, see next tutorial) are now also accessible; these are not part of this tutorial. Give the problem an informative name such as ‘Lixi-PBO pooled’ and click ‘Create’ at the bottom of the dialog.

Here you can define a new problem as a subset of all evidence (by excluding criteria and alternatives), and with different scale ranges.

## Create new problem

Enter new problem name

Reset to default

### Criterion and alternative selection


Settings


Criterion	Description	Units	<input checked="" type="checkbox"/> Lixisenatide	<input type="checkbox"/> Exenatide	<input checked="" type="checkbox"/> Placebo	Strength of evidence / Uncertainties	References
<b>Favorable effects</b>							
<input checked="" type="checkbox"/> HbA1c	Mean change i...	%	<input checked="" type="checkbox"/> -0.83		<input checked="" type="checkbox"/> -0.19		Pooled data from EFC6014 and EFC10743
			<input type="checkbox"/> -0.82		<input type="checkbox"/> -0.1		EFC6015
			<input type="checkbox"/> -0.79	<input type="checkbox"/> -0.96			EFC6019
<b>Unfavorable effects</b>							
<input checked="" type="checkbox"/> Nausea	Incidence of na...	%	<input checked="" type="checkbox"/> 26.9		<input type="checkbox"/> 7.3		Pooled data from all phase 2/3 controlled studies.
<input checked="" type="checkbox"/> Hypoglycaemia	Incidence of hy...	%	<input checked="" type="checkbox"/> 7.0		<input type="checkbox"/> 4.8		Pooled data from EFC6014 and EFC10743
			<input type="checkbox"/> 22.7		<input type="checkbox"/> 15.2		EFC6015
			<input type="checkbox"/> 2.5	<input type="checkbox"/> 7.9			EFC6019


Figure 5: Creating a problem


👉 Observe the effects table for the new problem. Note that the ‘Preferences’ tab has now become enabled. That tab and the ones to its right are the subject of the following tutorials.


## Create more effects tables

 Create another problem, this time selecting EFC6015 as data source for HbA1c and Hypoglycaemia, and indicate this fact in the title.


 When creating a new problem, the initially-selected criteria and alternatives are based on those of the current problem. The initial ‘Default’ problem always has everything selected, and thus may not be usable for analysis.

 Create another problem, but now to compare Lixisenatide and Exenatide. Note that, since there is no data source with measurements for Nausea for both alternatives, this problem must omit Nausea as a criterion.

 Use the ‘Problem’ dropdown at the top of the tab to switch between your effects tables. Observe that the effects table and browser URL changes whenever you switch problem.

 Creating a set of problems that all look at different aspects of your workspace’s data lets you contrast the alternatives in different ways. For each problem you can then define a further set of scenarios with different preferences regarding the importance of your criteria, and compare their benefit-risk balances (subject of the next tutorial).


## Workspace and view settings

 Click on the ‘settings’ button at the top of the tab (Figure 3). This lets you customise your view of the effects table and measurements in general. Take a moment to study the different settings you can choose. Play with the top three settings by changing their value and clicking ‘Save’, and observe the results. What should happen:


- Changing to Median/Mode does nothing (this only applies when the values shown in the effects table are sampled from probability distributions).
- Changing the ‘Effects display mode’ from ‘Deterministic – entered effects’ to ‘Deterministic – analysis values’ shows the values as they will be used for calculating the deterministic results. Changing to ‘SMAA – distribution parameters’ shows the distributions and their parameters

used for calculating the SMAA results. For this example the cells in the table will be empty, as no distributions were entered.

- Changing to ‘SMAA – analysis values’ shows the 95% confidence interval calculated from the distributions, however since we’ve only entered effects for this example, it will show the point estimate of those effects.
- Changing between percentages and decimals changes the shown values and units for Nausea and Hypoclycaemia but not HbA1c (this setting only affects dichotomous criteria). It will also only change the values on the two ‘analysis values’ views, as the other two show exactly what the input was.

 Uncheck e.g. the ‘Description’ and ‘Uncertainties / Strength of evidence’ checkboxes in the bottom section of the settings dialog to make the effects table more compact. Click ‘Save’ and study the result.

## Export effects table

 Open a rich text editor, such as MS Word, LibreOffice or Google Docs. Choose one of your effect tables, and click the ‘Copy to clipboard’ button (Figure 6). Now go to the editor and paste the selection in there. This should result in a structured table similar to the one in the browser. Depending on your editor and its settings, you may want to adjust things like whether there are borders around cells in your editor’s table settings.




Figure 6: Settings and copy buttons

## **Final words**

We hope that this tutorial has demonstrated adequately how to go from a wider data set to a smaller effects table that can be used to analytically study the benefit-risk balance of selected alternatives for selected criteria. We've also shown how to switch between such problems at will. Finally, we've shown how to change several aspects of how the effects table is displayed, and how to export your effects table to text editors e.g. for report writing.




## Tutorial 3: multi-criteria decision analysis


### Subjects covered


- Creating a new workspace based on an example dataset
- Exploring different methods for preference elicitation, that is, quantifying how important the benefits and risks of treatments are to you
- Seeing how these preferences impact the relative value of the evaluated treatments


### Sign in to MCDA.drugis.org


 Open your browser and navigate to <https://mcda.drugis.org>. Use your Google account to sign in.

### Create the example workspace

 Click the 'Create workspace' button. In the dialog that appears, choose 'Select tutorial workspace'. Now select the 'Zinbryta initial assessment simplified' option in the dropdown and press 'add'. You should now be on the Overview screen of a fresh workspace, like on Figure 7.

 The overview screen shows you the criteria and their data sources, the alternatives, and the table with measurement data.

 Many elements in the interface have a contextual help icon (Figure 8) that you can click for explanation and links to the relevant section in the manual.

 The example concerns a simplified version of the [Zinbryta assessment](#). The criteria are the primary endpoint (Annualised Relapse Rate) and several adverse events. Only data from the 205MS301 study are included, as can be seen in the effects table. The references column contains links to the clinicaltrials.gov registry version of this study in case you want to look at the source data.





Figure 7: The overview page

Effects Table 

Figure 8: Contextual help icon, outlined in red

## Evaluate evidence

 Go to the 'Problem definition' tab and take a moment to look at the effects table. Do you have a clear preference for one of the two treatments? What makes this treatment better in your view?

We are now going to quantify your preferences in several ways to see whether your intuitive answer in the previous step matches the outcome of the MCDA.

🎓 MCDA is a quantitative approach to benefit-risk assessment and ranks the evaluated treatments from least to most preferable. How preferable a treatment is, is reflected by its utility score. In ADDIS, a treatment's utility score is the sum of its per-criterion utility values. This method is called the additive value model.

🎓 Utility, as a constructed measure of well-being, has no natural scale. For simplicity, ADDIS (arbitrarily) uses the scale from 0 to 1, with 0 meaning the worst and 1 the best possible combination of the criteria scale values.

## Preferences: partial value functions

👉 Go to the 'Preferences' tab.

🎓 At the top are the partial value functions, which indicate how utility changes as a function of the criteria scale values. Below this is the weights section which is the main focus of this tutorial. Before setting weights, the partial value functions need to be defined.

👉 Click on the 'Define partial value function' button for ARR. Lower relapse rate is better, and we are going to assume that utility changes linearly with the relapse rate, so the type of function is 'Linear'. Click on 'Save' (see Figure 9).

The range over which the partial value functions are defined depends on the data included in the effects table. These ranges can be modified in the 'Problem definition' tab, but this goes beyond the scope of this tutorial.

👉 Also define linear partial value functions for the adverse event criteria, with low values being best. The result should look like Figure 10.

👉 (optional) Explore the process for defining non-linear partial value functions by clicking the 'Define partial value function' button under any of the functions, choosing the 'Piecewise-linear' option, and adjusting the sliders in the following steps. You can leave the definition process at any time by clicking on the 'Preferences' tab again.




Figure 9: Setting the ARR partial value function

🎓 Non-linear partial value functions are needed when equivalent changes on a criterion's measurement scale do not result in equivalent changes in utility. For example, one can imagine that going from severe depression to mild depression is more valuable than improving from mild to no depression (diminishing marginal utility).

## Preferences: ranking elicitation

First let's see how the treatments compare if we only give an ordinal ranking, with efficacy as the most important.

👉 Click the 'Ranking' button below the weights table, then indicate that ARR is the most important criterion, followed by Hep. AE, then Inf. AE. Then click on the 'Deterministic results' tab.

🎓 The deterministic results screen shows the effects table, with values that





Figure 10: The preferences tab after setting the partial value functions

can be changed to perform sensitivity analysis (subject of a later tutorial). Below this are the representative weights, showing which weights the system has used to calculate the value profiles. Because we did not supply direct numerical weights but did ordinal ranking instead, the system has generated a default set of weights consistent with the ranking provided. These so-called representative weights are shown in the table.

 The total value indicates an alternative's overall utility according to the weights you supplied and the data in the effects table. The value profile plot below the total value table shows the contributions of each criterion to these overall utility values (Figure 11). In the current situation, we can see that Daclizumab is much better at reducing the relapse rate, while the other treatment is better as far as all the adverse events goes. Because we have indicated that ARR is much more important than the adverse events, it follows that we should prefer Daclizumab.




Figure 11: Deterministic analysis

## Preferences: equal weights

Let's see how the picture changes if we weight all criteria equally.

👉 Go back to the 'Preferences' tab, and click the copy icon next to the scenario dropdown (Figure 12). Give the new scenario an intuitive name like 'Equal weights.'




Figure 12: Copy scenario button

🎓 Scenarios let you save different configurations of partial value functions and weights, and allow you to switch between them at will. New scenarios can be created as either a copy of the currently selected one, or completely blank, i.e. without defined partial value functions and weights.


👉 Click the 'Precise Swing weighting' button below the weights table, indicate that ARR is the most important, and then leave all the sliders at 100% and click 'Save'. Now navigate to the 'Deterministic results' tab again, and the results should be quite different. The representative weights are 0.25 for each criterion, and IFN  $\beta$ -1a 30 $\mu$ g is now better than Daclizumab. Because there are simply more adverse event criteria, they together outweigh the higher effectiveness of Daclizumab.

💡 You can switch between scenarios using the dropdown at the top of the tab, and the results will reload.

🎓 Precise Swing weighting lets you manually and precisely set the weights of all criteria relative to the most important one, as you have just done. Leaving all weights at 100% means they are all equally important. Imprecise Swing weighting similarly lets you set the weights, but allows you to specify probable intervals for the weights, for when you are less certain about your preferences or wish to see the consequences in stochastic analysis of uncertain weights.

## Preferences: matching elicitation

You can also determine your preferences by comparing alternative outcome scenarios, in the Matching elicitation process.

 Click the ‘Matching’ button under the weights table on the preferences tab. Select ‘ARR’ as the most important criterion in Step 1. In step 2, click the blue question mark in the row for ‘Hep. AE.’ In the dialog that appears (Figure 13), you are presented with a graph and two alternative scenarios. The graph is the indifference curve. You can change the value for ARR in Alternative B by clicking on it and moving the slider. This will update the graph. Change the value until you feel that the two alternatives are approximately equal, ie. decreasing ARR by a certain amount is ‘worth’ about that much increase in Hep. AE. Then click ‘Save’. The table will now have updated with the corresponding weight (Figure 14).





Figure 13: Matching elicitation (for one tradeoff)

 The indifference curve shows a line on which, according to your preferences, each point is equivalent, i.e. you should be indifferent between all the scenarios which the points on the line represent. The shape of the indifference curve depends on your weights and your partial value functions (pfvs). If both pfvs are linear, the indifference curve is always a straight line, but



## Matching (2/2) ?

Criterion ?	Description	Unit ?	Worst	Best	Importance
ARR	Unadjusted annualised relapse rate		0.393	0.212	100%
Hep. AE	Incidence of hepatobiliary events	%	0.16	0.14	60%
Cut. AE	Incidence of cutaneous reactions	%	0.37	0.19	?
Inf. AE	Incidence of infections	%	0.65	0.57	?

Cancel Previous

Figure 14: Matching elicitation: overview

in the case of nonlinear pvfs the curve may become non-linear. Feel free to experiment with this.

👉 Finish filling out your preferences in the Matching elicitation and go to the Deterministic results tab to see how the values of the treatments have changed. Are these results in line with your intuitive assessment at the beginning of the tutorial?

## Final words

This tutorial has demonstrated how assigning different importance to criteria can drastically change the relative value of the evaluated treatments. We've also shown how quantifying these importances makes it easy to see where these differences originate. Finally, we've shown that in the MCDA interface it is easy to input different preference scenarios and switch between them.

## Tutorial 4: sensitivity analysis


MCDA requires exact preference weights. However, in most benefit-risk assessment situations such exact weights are not available; they might lie on a range or simply be unknown. Further, the supplied data might have significant variance. In this tutorial we will investigate several ways to determine how sensitive the results of analyses are to such uncertainties.

### Subjects covered


- Uncertainty in data and preferences
- Deterministic sensitivity analysis
- Stochastic sensitivity analysis


**⚠** Note that this tutorial continues from the simplified version of the [Zinbryta assessment](#) used in the previous tutorial about benefit-risk analysis. At several points during this tutorial we ask you to compare results to those of the previous one, so it is helpful to have your work from the previous tutorial open in a separate browser tab or window.

### Sign in to MCDA.drugis.org


 Open your browser and navigate to <https://mcda.drugis.org>. Use your Google account to sign in.


### Create the example workspace

 Click the ‘Create workspace’ button. In the dialog that appears, switch to ‘Select tutorial workspace’ and choose the ‘Zinbryta initial assessment simplified, stochastic’ option. You should now be on the Overview screen of a fresh workspace. Open the settings dialog and switch the ‘Effects table display mode’ to ‘SMAA - distribution parameters’. Note the point estimates have confidence intervals for all measurements.


 For this tutorial example, we indicated explicitly when entering the data that we assume they are approximately normally distributed for their given point estimate and confidence interval (see Figure 4 in the first tutorial).


This lets their distributions be used to perform stochastic sensitivity analysis, as explained towards the end of this tutorial.


 Click on the ‘Problem definition’ tab. Consider how the confidence intervals for each criterion’s measurements are connected to the ‘Observed Range’ column in the scale ranges table.


 The scale ranges for each criterion determine which highest and lowest values to consider when defining their partial value functions. Scale ranges can be wider than the observed data, but never narrower. If the data include uncertainty the confidence intervals are included in the scale ranges.

## Deterministic sensitivity analysis

 Click on the ‘Preferences’ tab and define your partial value functions, as in our previous tutorial on benefit-risk analysis. Remember that lower is better for all criteria in this analysis. Note that the X-axis of each pvf corresponds to the scale range for that criterion.

 Perform an ordinal ranking, with ARR most important, and the AEs in decreasing importance from top to bottom. Go to the ‘Deterministic results’ tab, and look at the ‘Value profiles’ plot. Compare it to the ‘Value profiles’ plot of the previous tutorial’s ordinal ranking scenario. Note that both alternatives derive some value from each criterion. Also note that now that uncertainty is included, Daclizumab actually has higher value.

 Widening the scale ranges of your criteria is one way of incorporating uncertainty in your analyses. Since the partial value function for a criterion by definition returns an extreme value (either 0 or 1) at the minimum or maximum value of the scale range, measurements at these extremes will therefore have either maximally positive or maximally negative value. If you widen your scale ranges so that your measurements are never at these extreme ends, they will always have some positive contribution to that alternative’s value.

 Let’s see what happens if we want to consider the case where the point estimate for ARR is too high for IFN  $\beta$ -1a 30 $\mu$ g. Click on this value in the effects table at the top of the page, and change it to approximately 0.353: the lowest value within the 95% C.I. (Figure 15). Click the ‘Recalculate value

profiles' button below the effects table, and take a look at the new results. As it turns out, this single change is not sufficient to change the benefit-risk balance.




Figure 15: Changing the effect value

📖 Scroll down to the bottom of the page and take a look at the plots in the 'One-way sensitivity analysis' section. These give some insight into what the consequences of changing a single value would be. In the left ('Measurements') plot select IFN  $\beta$ -1a 30 $\mu$ g as the alternative and observe the changes. Pay particular attention to the intersection point of the two lines.

🎓 The measurements plot of the one-way sensitivity analysis shows you how the total value of a criterion changes if you change its measurement for a specific alternative, while keeping all other values constant. In other words, we could have predicted that the change we made in the previous step (to 0.353) would not be sufficient to upset the benefit-risk balance, because the intersection point with the Daclizumab is only at approximately 0.3125. The measurements plot thus lets you explore the sensitivity of the benefit-risk

balance to each individual effect. Note that for linear pvfs this is rather straightforward, but nonlinear ones make it more interesting.

🎓 Similarly, the ‘Preferences’ plots let you see how the value of all alternatives changes with the weight of a specific criterion. Note that, since all weights should always sum to 1, this means that the weights of the other criteria also change implicitly. Instead of their value, their proportional share of the remaining weight is kept constant.

🎓 Deterministic analysis lets you easily predict the results of a single change, and check the consequences of different measurement data. However, it would be extremely labour-intensive to manually make a lot of changes and aggregate the results into an overview of the possibilities given the measurements, your preferences, and their uncertainties. This need is addressed by stochastic multicriteria acceptability analysis (SMAA) which we’ll briefly discuss in the next section.

## Stochastic sensitivity analysis

🔑 Go to the ‘SMAA results’ tab. Take a moment to look at the outputs. Most important are the rank acceptability plot and table at the top of the page (Figure 16). These indicate how frequently each alternative had a specific rank in the different configurations of measurements and preferences that were generated.

🎓 SMAA models explore uncertainties in the measurements and preferences by systematically varying their values<sup>1</sup>. The set of variations (of which there can be hundreds of thousands) can be analysed in several ways. We here use the rank acceptability: for each variation the alternatives are ranked according to their calculated value, and then the proportion of variations in which an alternative had each specific rank is reported.

🔑 Go to the ‘Preferences’ tab, create a new scenario called ‘100-75-50-25’. Set the partial value functions as before, and use Precise Swing to set the Criteria weights as: ARR 100%, Hep. AE 75%, Cut. AE 50% and Inf. AE

---

<sup>1</sup>SMAA samples from probabilistic distributions for these values - for a more in-depth explanation of the process, see the [MCDA manual](#) and Tervonen & Lahdelma (2007)



Figure 16: Rank acceptabilities

25%. Go to the ‘Deterministic results’ tab, and you should see that the value of both alternatives is approximately equal. Now navigate to the ‘SMAA’ tab and observe the results. You should see that each alternative is ranked as best in roughly 50% of all cases. This is consistent with the deterministic analysis, where the value for both alternatives is approximately equal.

📖 Switch to your workspace from the previous tutorial. Create a scenario in the Preferences tab called ‘ranked weights’, then use Precise swing to specify the weights as: ARR 100%, Hep. AE 50%, Cut. AE 25% and Inf. AE 12%. This results in a representative weight distribution approximately equal to the one automatically generated for deterministic analysis of the case where the criteria are ranked.

📖 Go to the ‘Deterministic results’ tab and use the scenario switching to go back and forth between the ‘ranked weights’ scenario and the ‘Default’ one (assuming you kept that scenario as using ranking; otherwise do a new ranking elicitation). The results and representative weights should be similar.

☞ Switch to the ‘SMAA results’ tab and again switch back and forth between the two scenarios. Now you should see a great difference. For the specific weight distribution we picked, there is no uncertainty in either the measurements or the preferences, and thus all scenarios result in the same ranking. However, in the ‘Default’ scenario where only ranks are specified, the different ways in which the weights can be distributed while preserving their ranking are taken into account, showing that for only approximately half such rankings Daclizumab 150mg is better than IFN  $\beta$ -1a 30 $\mu$ g.

🎓 Uncertainty can also lie in the preferences. If only a ranking is specified, there are infinitely many ways to pick the actual weight values for the criteria that still satisfy the given ranking. SMAA also varies the preferences if there is uncertainty there.

## Final words

This tutorial showed how to explore potential consequences of uncertainty in your measurements and preferences for the benefit-risk balance. It also demonstrated how to determine the sensitivity of the benefit-risk balance to changes in measurements and preferences. Finally, we’ve shown how to interpret the output of SMAA models and their bird’s eye view of what is possible.